---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Storage and supply questions"
description: "Storage and supply questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Tablet and Storage. Questions: What strengths does Ubrelvy come in, and what do the tablets look like? How should Ubrelvy be stored? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Storage and supply questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Tablet

<a id="ubrelvy-tablet-appearance"></a>

### What strengths does Ubrelvy come in, and what do the tablets look like?

> “UBRELVY 50 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed 
> with “U50” on one side.”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

> “UBRELVY 100 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed 
> with “U100” on one side.”

Source: [UBRELVY: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=3)

## Storage

<a id="ubrelvy-storage"></a>

### How should Ubrelvy be stored?

> “Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C 
> (59°F and 86°F) [see USP Controlled Room Temperature].”

Source: [UBRELVY: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=14)

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
